HOME > TOP STORIES

TOP STORIES

BUSINESS Daiichi Sankyo Taps EVP Manabe as Next President

February 1, 2017
BUSINESS Major Products Face Impending Listing of Generics, though Patents Remain for Some

February 1, 2017
REGULATORY MHLW, Pharma Industry Officials Agree on Conditional Early Approval System

January 31, 2017
COMMENTARY Top-Notch Talents Needed for Pharma’s Lobbying Activities; Stay Current with Policymaking Moves

January 30, 2017
BUSINESS Daiichi Sankyo Espha to Launch Micardis AG, Will Actively Handle Competitors’ Products

January 27, 2017
REGULATORY MHLW Warns Against Purchasing Harvoni in Unpackaged Bottles

January 26, 2017
REGULATORY (Update) Chuikyo Agrees to Shed US Price from Foreign Price Adjustment Rule

January 25, 2017
REGULATORY Counterfeit Harvoni Found in Tokyo Too, Route Identified for a Nara Bottle

January 24, 2017
BUSINESS Ferring Speeding Up R&D in Core Sectors, Positive on Licensing and M&A: Japan CEO

January 23, 2017
ORGANIZATION JGA Head Frets Majority of Products Subject to Gap-Year Revisions Will Be Generics

January 20, 2017
BUSINESS Gilead Japan to Switch Sovaldi, Harvoni Bottles to Blister Packs

January 19, 2017
ORGANIZATION JMA’s Nakagawa Pushes Price Cuts Even on Non-100 Billion Yen Products, Eyes Other Hep C Drugs

January 18, 2017
REGULATORY Counterfeit Harvoni Discovered in Nara Pharmacy, MHLW Investigating Route of Entry into Distribution

January 18, 2017
REGULATORY MHLW to Ponder Additional Gap-Year Price Survey Method That Won’t Cripple Single-Product, Single-Price Efforts: Kanda

January 17, 2017
INTERVIEW MHLW’s Sakoi Calls on Industry to Transcend Corporate Boundaries, Join Pricing Reform Debate

January 16, 2017
REGULATORY PMDA Stops Increasing Review Staff, Current Review-Time Targets to Remain Unchanged: Chief Executive

January 16, 2017
REGULATORY Industry Speculating Tax Hike Will Delay Annual Revision Rollout to 2021

January 13, 2017
REGULATORY Chuikyo Industry, Doctor Reps in Discord over Scope of Price Review for Indication Expansions

January 12, 2017
BUSINESS Ariad Deal Is “Global Acquisition” Not Limited to US Market: Takeda CEO

January 11, 2017
REGULATORY Chuikyo to Kick Off Debates to Elaborate Pricing Revamp; 2 Industry Hearing Sessions Planned

January 11, 2017

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…

COMMENTARY

Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?

By Hayate Horiguchi

Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…